News >

Atezolizumab Regimen Improves PFS in Frontline Nonsquamous NSCLC

Kristie L. Kahl
Published: Tuesday, Sep 25, 2018

Vassiliki A. Papadimitrakopoulou, MD

Vassiliki A.

Papadimitrakopoulou, MD
The addition of atezolizumab (Tecentriq) to carboplatin/cisplatin in the first-line setting and to pemetrexed as maintenance therapy significantly improved progression free survival (PFS) in patients with stage IV nonsquamous non–small cell lung cancer (NSCLC).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x